Biomarkers are critical tools for detecting and monitoring disease, understanding pathogenic mechanisms, and tracking therapeutic responses. From proteomic profiling to AI-based algorithms, scientists ...
This eBook highlights the emerging trends, technologies, and translational strategies shaping biomarker discovery and its application across oncology, neurology, immunology, and beyond.
A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson's disease in its earliest stages, before extensive brain damage has ...
Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery market ...
Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development BOSTON--(BUSINESS WIRE)-- Genialis, the RNA biomarker company, ...
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS patients, which is carried to the CNS, where it binds to and damages neurons ...
NEW YORK CITY, NEW YORK / ACCESS Newswire / September 25, 2025 / Lunai Bioworks Inc. (NASDAQ:RENB), an AI-powered drug discovery company and parent of wholly owned subsidiary BioSymetrics, today ...
Researchers have traditionally employed histopathology techniques, which involve the microscopic examination of tissue, to gain insight into disease processes. This approach often leads to subjective ...
microRNAs are emerging as powerful biomarkers for precision medicine, offering valuable insights into disease mechanisms, diagnosis, prognosis, and treatment response. However, successful discovery ...
The advent of multiomic approaches has significantly improved early cancer detection by integrating diverse molecular data to gain a more complete understanding of disease processes. While advances in ...
Plasma proteomics offers great promise for biomarker discovery, due to the accessibility and diagnostic relevance of blood plasma. Recent advances in instrumentation, particularly the Orbitrap Astral ...
BOSTON--(BUSINESS WIRE)--Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results